Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

First Launch Commercialization Strategy: Go It Alone or Partner?

Posted by Renuka Agarwal on Fri, Feb 01, 2019

Ben Hohn, Cody Powers and Judith Kulich co-wrote this article with Renuka Agarwal.

The 2019 JPMorgan Chase Healthcare Conference kicked off with a bang as Eli Lilly announced its acquisition of Loxo Oncology for $8 billion. Loxo, a young biotechnology company that partnered with Bayer to launch its first asset, Vitrakvi, in 2018, isn’t a unique story: In today’s environment, the number of first launches for U.S.-based companies—defined by ZS as the first marketed assets of companies that have FDA “novel” status—is rapidly increasing. There were only three first launches from U.S.-based companies in 2011 compared to an astounding 16 first launches in 2018, primarily in oncology, according to ZS research.

Read More

Topics: Pharma, Pharma Industry, Life Sciences, commercial landscape, commercialization, european market, US-first launch, pharma commercial model, pharma strategy, JPMorgan Healthcare Conference, JPM2019

Subscribe to The Active Ingredient
SUBSCRIBE

Get 'THE ACTIVE INGREDIENT' Updates

Subscribe to receive email notifications whenever new blog posts are published.

×